These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31257551)

  • 1. Correction to: Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
    Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
    Neurol Sci; 2019 Sep; 40(9):1925-1926. PubMed ID: 31257551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies.
    Olivola E; Fasano A; Varanese S; Lena F; Santilli M; Femiano C; Centonze D; Modugno N
    Neurol Sci; 2019 Sep; 40(9):1917-1923. PubMed ID: 31111272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
    Drapier S; Vérin M
    Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
    Borgemeester RWK; van Laar T
    Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
    Pietz K; Hagell P; Odin P
    J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):709-16. PubMed ID: 9810943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B; Domzał T
    Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors.
    Bhidayasiri R; Sringean J; Anan C; Boonpang K; Thanawattano C; Ray Chaudhuri K
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S36-S41. PubMed ID: 27939326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.
    Bhidayasiri R; Boonpang K; Jitkritsadakul O; Calne SM; Henriksen T; Trump S; Chaiwong S; Susang P; Boonrod N; Sringean J; van Laar T; Drent M; Chaudhuri KR
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S49-S55. PubMed ID: 27939324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.
    Reuter I; Ellis CM; Ray Chaudhuri K
    Acta Neurol Scand; 1999 Sep; 100(3):163-7. PubMed ID: 10478579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.
    Borgemeester RW; Drent M; van Laar T
    Parkinsonism Relat Disord; 2016 Feb; 23():17-22. PubMed ID: 26709292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
    Stocchi F; Vacca L; De Pandis MF; Barbato L; Valente M; Ruggieri S
    Neurol Sci; 2001 Feb; 22(1):93-4. PubMed ID: 11487217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.
    Battaglia G; Busceti CL; Cuomo L; Giorgi FS; Orzi F; De Blasi A; Nicoletti F; Ruggieri S; Fornai F
    Neuropharmacology; 2002 Mar; 42(3):367-73. PubMed ID: 11897115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
    Wenzel K; Homann CN; Fabbrini G; Colosimo C
    Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson's Disease: The APO-NIGHT Study.
    Fernández-Pajarín G; Sesar Á; Ares B; Castro A
    J Parkinsons Dis; 2016 Oct; 6(4):787-792. PubMed ID: 27662329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.